Zacks Industry Rank Analysis Highlights: Abbot Laboratories, AstraZeneca, Chattem,...

Zacks Industry Rank Analysis Highlights: Abbot Laboratories, AstraZeneca, Chattem, Cubist Pharmaceuticals and ViroPharma

CHICAGO--(Business Wire)--
Zacks.com releases the latest Zacks Industry Rank. Stocks featured
in this week's analysis includes Abbott Laboratories (NYSE: ABT),
AstraZeneca (NYSE: AZN), Chattem (Nasdaq: CHTT), Cubist
Pharmaceuticals (Nasdaq: CBST) and ViroPharma (Nasdaq: VPHM).

To see the Zacks Industry Rank and the trend in earnings estimates
revisions for more than 200 industry groups, visit
http://at.zacks.com/?id=3154.

Zacks Industry Rank Analysis is written by Charles Rotblut, CFA,
Senior Market Analyst for Zacks.com.

This week: Unexpected Industries With Bullish Forecasts

Key Points:

-- The credit crunch, combined with continued market volatility,
has many investors looking at more conservative sectors.

-- Medical-Drugs (http://at.zacks.com/?id=4921) not only is a
less economically-sensitive group, but also offers growth
opportunities

-- Analysts have become more bullish on drug stocks

-- Medical-Drugs contains 7 Zacks #1 Rank ("strong buy") and 27
Zacks #2 Rank ("buy") stocks

Big Earnings For Large-Cap Pharma

Abbott Laboratories (NYSE: ABT) topped expectations last week and
raised its full-year guidance.

The large-cap pharmaceutical company earned 79 cents per share in
the third quarter, besting expectations by 2 cents. It was the 3rd
positive surprise in 4 quarters. Net income rose 18.1% to $1.24
billion.

Revenues rose 17.6% to $7.5 billion. Several of ABT's divisions
delivered double-digit growth: Nutritionals (+15%), Pharmaceuticals
(+17%), Diagnostics (+15%) and Vascular (+58%).

Contributing to the growth was Humira, an anti-inflammatory
treatment for rheumatoid arthritis and psoriasis, and Depakote, used
for seizures. Humira not only saw higher sales, but also gained market
share. ABT is also experiencing higher demand for its nutritional
products from emerging markets. Finally, the launch of XIENCE V, a
drug-eluting stent, had a stronger-than-expected launch.

Following the strong performance, Abbott Laboratories revised its
full-year guidance to between $3.31 and $3.33 per share. All 11 of the
covering brokerage analysts adjusted their profit projections in
response, pushing the consensus earnings estimate 5 cents higher to
$3.32 per share.

The majority of these analysts also raised their fiscal 2009
forecasts. The new consensus earnings estimate of $3.68 per share is 3
cents higher than the average forecast of a week ago.

ABT is a Zacks #2 Rank ("buy") stock.

Good Profits For Smaller Pharmaceutical Companies, Too

Cubist Pharmaceuticals (Nasdaq: CBST) joined ABT by issuing a
bullish earnings report last week.

Third-quarter profits totaled 44 cents per share, 10 cents above
expectations. It was the 3rd consecutive surprise for the company.

Revenues jumped 41% to $112.4 million. Antibiotic CUBICIN(R) not
only saw more prescriptions written, but also gained market share
against its primary competitor. Net product revenue from the drug
totaled $109.2 million.

The company also saw some early success with MERREM, a treatment
for skin infections. Cubist is marketing MERREM in the U.S. for
AstraZeneca (NYSE: AZN). Management believes sales of this treatment
will have a large impact in the fourth quarter.

Nearly all of the covering brokerage analysts raised their 2008
profit projections following the release of the third-quarter results.
CBST is now projected to earn $1.24 per share this year, up 16 cents
from last week's average forecast of $1.08 per share.

CBST is also Zacks #2 Rank ("buy") stock.

Estimates Also Raised On Other Drug Companies

As noted above, the Medical-Drugs group contains 10 Zacks #1 Rank
("strong buy") stocks, including AZN and ViroPharma (Nasdaq: VPHM),
and 27 Zacks #2 Rank stocks, including Chattem (Nasdaq: CHTT).

AstraZeneca, which makes the acid reflux drug Nexium, is not
expected to report until early November. Within the past few weeks,
however, 2 of the 8 covering brokerage analysts raised their full-year
forecasts. The revisions have pushed the consensus earnings estimate 4
cents higher to $4.85 per share.

ViroPharma will report next Wednesday, Oct 29. Ahead of the
report, 3 of the 9 covering brokerage analysts have raised their
third-quarter forecasts. The revisions, however, were not large enough
to move the consensus earnings estimate, which continues to sit at 23
cents per share.

As part of its earnings release, VPHM could provide an update on
Cinryze, which treats angioedema attacks (swelling underneath the
skin). The company received FDA approval 2 weeks ago and is expected
to launch the drug this quarter. Cinryze could achieve sales of $250
million to $300 million, which would have a significant impact on
overall revenues and earnings.

Chattem, which markets over-the-counter treatments such as
Coritzone-10 and Icy Hot, raised its fiscal 2008 guidance late last
month. The company now projects that fiscal 2008 earnings will be
between $4.20 and $4.25 per share, versus the previous guidance of $4
to $4.20 per share.

CHTT also issued initial fiscal 2009 guidance of $4.80 to $5 per
share.

Both forecasts were above the consensus earnings estimates. In
response, the majority of the covering brokerage analysts revised
their forecasts higher. The new consensus earnings estimates are at
$4.05 for fiscal 2008 and $4.67 for fiscal 2009.

Zacks "Profit from the Pros" e-mail newsletter offers continuous
coverage of the industries and the stocks poised to outperform the
market. Subscribe to this free newsletter today by visiting
http://at.zacks.com/?id=2564.

Visit http://www.zacks.com/performance for information about the
performance numbers displayed in this press release.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which
was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was the
formation of his proprietary stock picking system; the Zacks Rank,
which continues to outperform the market by nearly a 3:1 margin. The
best way to unlock the profitable stock recommendations and market
insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your
free subscription to Profit From the Pros by going to
http://at.zacks.com/?id=2565.

Zacks Investment Research is under common control with affiliated
entities (including a broker-dealer and an investment adviser), which
may engage in transactions involving the foregoing securities for the
clients of such affiliates.

Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an offer
or solicitation to buy or sell any security.

Zacks.com
Charles Rotblut, CFA
Phone: 312-265-9352
Email: pr@zacks.com
Visit: www.Zacks.com

Copyright Business Wire 2008